Minori Rosales - 24 Jan 2022 Form 4 Insider Report for Sesen Bio, Inc. (CARM)

Role: Chief Development Officer
Signature: /s/ Mark R. Sullivan, as attorney-in-fact
Issuer symbol: CARM
Transactions as of: 24 Jan 2022
Net transactions value: $0
Form type: 4
Filing time: 26 Jan 2022, 19:27:54 UTC
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CARM	Common Stock	Award	$0	+623,000		$0.000000	623,000	24 Jan 2022	Common Stock	623,000	$0.7330	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	25% of the shares subject to such option shall vest on the first anniversary of the date of grant of the option and an additional 6.25% of the shares underlying the option shall vest at the end of each successive three-month period thereafter until the fourth anniversary of the date of grant of the option. Based on market analysis by Radford of public, pre-commercial and commercial biopharmaceutical companies, the compensation committee of Sesen Bio, Inc ("the Company"), recommended to the Company's board of directors, and the board of directors approved, the grant to the reporting person.

Content

25% of the shares subject to such option shall vest on the first anniversary of the date of grant of the option and an additional 6.25% of the shares underlying the option shall vest at the end of each successive three-month period thereafter until the fourth anniversary of the date of grant of the option. Based on market analysis by Radford of public, pre-commercial and commercial biopharmaceutical companies, the compensation committee of Sesen Bio, Inc ("the Company"), recommended to the Company's board of directors, and the board of directors approved, the grant to the reporting person.